Ontology highlight
ABSTRACT: Introduction
Many patients with lung cancers cannot receive platinum-containing regimens owing to comorbid medical conditions. We designed the PPB (paclitaxel, pemetrexed, and bevacizumab) regimen to maintain or improve outcomes while averting the unique toxicities of platinum-based chemotherapies.Methods
We enrolled patients with untreated, advanced lung adenocarcinomas with measurable disease and no contraindications to bevacizumab. Participants received paclitaxel, 90 mg/m(2), pemetrexed, 500 mg/m(2), and bevacizumab, 10 mg/kg, every 14 days for 6 months and continued to receive pemetrexed and bevacizumab every 14 days until progression or unacceptable toxicity.Results
Of the 44 patients treated, 50% were women; the median age was 61 years and 89% had a Karnofsky
SUBMITTER: Pietanza MC
PROVIDER: S-EPMC4877255 | biostudies-literature | 2016 Jun
REPOSITORIES: biostudies-literature